Maculaser develops novel medical technology for treatment of common retinal diseases, including diabetic macular edema and dry age-related macular degeneration. The core of the company’s innovation is the precise temperature control of the macula during non-damaging laser treatments; a potential game changer in the practice how retinal diseases, with over 200B EUR direct health care costs, are being treated in the future.


    • Founding year:

    • Development phase:

    • Funding:
Seed / A round

    • Website: 

    • Contact person info: 

    • Team members: 

    • Article:
Read an article about Maculaser.